IL13 and COVID-19: In another retrospective analysis using a large COVID-19 international cohort, people who had been receiving treatment for severe asthma with Dupilumab, a monoclonal antibody that blocks IL-13 and IL-4 signalling, demonstrated a lower risk of ventilation and death from COVID-19 [82].